AI for Multi-Omics Driven Development of Cell Therapies
Design and produce more effective cell therapies using the comprehensive profile of cell therapy product to link cell states with therapy efficacy and treatment success.
Moonshot startup from UC Berkeley SkyDeck
We improve the design of T-cell therapies today — to make them more efficient and safer for patients tomorrow
Trusted by teams at
and the global community of 45,000 medical scientists and researchers worldwide
Pfizer · Novartis · UCSF · Stanford · MIT · MD Anderson Cancer Center ·
The Johns Hopkins University School of Medicine
"Using the platform has been extremely helpful in producing beautiful publication ready plots for visualizing how clonotypes change across different timepoints. The platform takes hours off data analysis by providing a tool to easily analyze multiple data files and run biomarker discovery in a very smooth and quick way."
— Molly B. El Alam, MPH. Research Assistant, Department of Radiation Oncology, The University of Texas M.D. Anderson


"The platform has been incredibly helpful with analyzing and interpreting our data. When I reached out with questions, Vadim (Co-Founder/ CEO ImmunoMind) was very helpful and responsive. I'm grateful to ImmunoMind for making this critical analysis program."
— Senior Researcher, TOP-5 Pharma company
"I used the platform to analyse TCR expression in RNAseq data from human skin. It is very handy even without strong prior knowledge in programming and R!"
Irène Gallais, PhD, MD, Dermatologist in Besancon University Hospital France, affiliated to CMM, Karolinska Institute, Sweden
Platform benefits.
Design better T-cell therapies using ImmunoMind's actionable insights
Streamline collaborative work across teams, stages and trials
Leverage single-cell and bulk multi-omics technologies for T-cell therapy development
ImmunoMind's Multi-Omics Intelligent Platform guides translational and clinical research to help design better T-cell therapies using proprietary computational immunology and AI technologies
Design better T-cell therapies using ImmunoMind's actionable insights
Help medical scientists in decision-making by precisely identifying T-cell subpopulations and their immune profile associated with the drug's efficiency and toxicity.
Automatically estimate subpopulations' exhaustion rate, evaluate cell differentiation, and identify off-tumor targets with ImmunoMind's proprietary technologies.
Streamline collaborative work across teams, stages and trials
Accelerate collaboration and communication between medical scientists and bioinformaticians from translational and clinical research groups.
ImmunoMind's secure infrastructure ensures full reproducibility of every insight.
Leverage single-cell and bulk multi-omics technologies for T-cell therapy development
Unique bioinformatics capabilities to support translational and clinical research.
Extract actionable insights from single-cell and bulk transcriptomics, immunogenomics and other -omics using optimized proprietary technologies.
Applications.
Request for the "Compare essential CAR-T cell population characteristics and choose the most prominent drug candidates" application details
Please fill up the form and we'll be in touch soon
Request for the "Apply novel strategies to improve the CAR-T product's efficacy by exhaustion estimation" application details
Please fill up the form and we'll be in touch soon
Request for the "Address the extensive heterogeneity of CAR-T drugs to reduce toxicity" application details
Please fill up the form and we'll be in touch soon
Request for the "Improve the CAR-T manufacturing process using cell differentiation insights" application details
Please fill up the form and we'll be in touch soon
Partner with us.
Emerging Biotech Partnerships
ImmunoMind helps emerging biotechnology companies and university spin-offs de-risk their T-cell therapy on the crucial discovery steps and help with multi-omics data infrastructure.
Biopharma Partnerships
ImmunoMind partners with the world's leading pharmaceutical and biotechnology companies to help design better T-cell therapies on preclinical and clinical stages.
Research Partnerships
ImmunoMind collaborates with academic and government research institutes to study immune cell biology and discover new T-cell therapies.